Magnesium sulfate heptahydrate USP is filled into single-dose sachets as an oral saline laxative at a reference adult unit dose of 5 g, dispersed in 240 mL of water immediately before administration. The crystalline API is delumped through a conical mill fitted with a 1.0 mm screen at 1200 min⁻¹, then blended with a pre-sieved citric acid–sodium bicarbonate effervescent pair only where an effervescent presentation is specified; non-effervescent oral powder is filled directly after delumping. Particle-size control between 180 µm and 850 µm is maintained because the fines fraction accelerates dissolution but segregates in rotary sachet filler hoppers, while coarse crystals dissolve too slowly and produce a gritty mouthfeel. Sachet fill-weight variation is verified against USP <905> at n=20 units, and blend uniformity samples are drawn from 10 positions after 15 min of mixing in a 600 L bin blender. Because the heptahydrate contains 51.2% water of crystallization by mass, aqueous granulation is deliberately avoided; when a granulated presentation is required, a top-spray fluid-bed granulator with an isopropanol-based binder solution and inlet air temperature not exceeding 40 °C is used. The dried granules are tested for loss on drying by USP <921> and maintained at 48–52% to preserve hydrate stoichiometry. The terminal product is a clear to slightly turbid oral solution after dispersion and is labeled as a saline laxative.

How Does Hydrate Loss Constrain Tablet and Capsule Production?

In solid oral dosage forms intended for magnesium replacement, magnesium sulfate heptahydrate is formulated in unit strengths of 250 mg to 500 mg elemental magnesium per tablet or capsule, equivalent to approximately 1.03 g to 2.06 g of the heptahydrate per unit when label claim is expressed as elemental magnesium. The high salt loading and water of crystallization impose a compression constraint: direct compression on a rotary press with excessive dwell pressure can induce localized die-wall heating, release hydrate water, and increase punch adhesion. Roller compaction is therefore preferred; a starting ribbon thickness of 0.8 mm and roll force of 12 kN/cm are qualified on the selected equipment, and compacted granules are milled through a 1.0 mm screen before blending with 1.0 wt% magnesium stearate and 0.5 wt% colloidal silicon dioxide. Dissolution is evaluated by USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid, with an immediate-release specification of not less than 75% dissolved at 30 min. Enteric-coated tablets are film-coated with a methacrylic acid copolymer system to a weight gain of 8–12%, then tested for acid resistance in 0.1 N hydrochloric acid for 2 h followed by buffer-stage release at pH 6.8. Finished units are packaged in HDPE bottles with desiccant canisters because residual moisture drives caking and soft gelatine shell deformation.For intravenous hypomagnesemia correction and the acute management of torsades de pointes, magnesium sulfate injection USP is manufactured as a 50% w/v concentrate, equivalent to 500 mg/mL magnesium sulfate heptahydrate and 4.06 mEq/mL magnesium ion, supplied in 10 mL and 20 mL single-dose vials. The solution is prepared by dissolving USP-grade magnesium sulfate heptahydrate in Water for Injection at 25 °C with continuous agitation, followed by filtration through a 0.22 µm sterilizing filter and terminal sterilization at 121 °C for 15 min, validated to deliver a minimum F₀ of 15 min. The 50% w/v solution has a density of approximately 1.22 g/mL, so gravimetric fill control is used rather than volumetric fill to reduce fill-volume error. The USP monograph for Magnesium Sulfate Injection requires assay between 93.0% and 105.0% of the labeled amount, pH of the diluted solution between 5.0 and 8.0, bacterial endotoxins not more than 0.03 EU/mg of magnesium sulfate, and particulate matter limits per USP <788> for small-volume injectables. For intravenous infusion, the concentrate is diluted with 0.9% sodium chloride injection or 5% dextrose injection to a final concentration not exceeding 20% w/v for peripheral administration because higher concentrations are associated with osmotic injury; central venous administration may use 20% solutions. The terminal product is a sterile, nonpyrogenic parenteral solution intended for dilution before intravenous use.

Parameter	Method/Reference	Oral Powder/Granule	Injection
Assay (MgSO4, dried basis)	USP Magnesium Sulfate monograph	99.0–100.5%	93.0–105.0% of labeled amount
Bacterial endotoxins	USP <85>	Not specified	NMT 0.03 EU/mg magnesium sulfate
pH (5% aqueous solution)	USP <791>	5.0–8.0	5.0–8.0
Particulate matter	USP <788>	Not specified	SVP limits
Sterility	USP <71>	Not required	Sterile

When Magnesium Sulfate Is Compounded into Total Parenteral Nutrition Admixtures

The addition of magnesium sulfate injection to total parenteral nutrition admixtures provides magnesium at final concentrations of 4–20 mEq/L, depending on the amino acid profile and patient-specific electrolyte requirement. The compounding sequence is controlled because magnesium and calcium compete for phosphate in the admixture; magnesium sulfate is added to the dextrose–amino acid base before calcium gluconate, and the completed formulation is visually inspected against a light source and periodically filtered to detect precipitation. The pH of the admixture is maintained between 5.0 and 6.0 using acetic acid or malic acid buffers, which reduces the dibasic phosphate concentration responsible for insoluble calcium and magnesium phosphate formation. When 10% calcium gluconate injection is present, the total calcium plus magnesium milliequivalents are calculated against the phosphate load; published admixture stability data for the specific amino acid formulation must be consulted, because precipitation may not be visible immediately and can develop over 24–48 h at 2–8 °C storage. Compounded TPN is passed through a 0.22 µm filter, stored under refrigeration, and administered through a central venous catheter because final osmolality is typically 800–1200 mOsm/kg. The magnesium content is verified on a pull sample by atomic absorption spectrophotometry or ion chromatography before release.

Obstetric Seizure Prophylaxis, Dilution Limits, and Line Compatibility

Magnesium sulfate injection is used in obstetric hospital protocols as an intravenous loading infusion of 4 g diluted to 20% w/v or less, followed by a maintenance infusion of 1–2 g/h via controlled-rate infusion pump. The drug product is compounded in hospital pharmacy cleanrooms under USP <797> conditions, using single-dose vials within 12 h of first needle puncture outside an ISO 5 hood. Dilution is performed with 0.9% sodium chloride injection in polyvinyl chloride or polyolefin infusion bags; the final concentration is not to exceed 20% w/v for peripheral administration. Incompatibility is documented with carbonate and phosphate salts, which form insoluble magnesium carbonate and magnesium phosphate; calcium-containing solutions are administered through a separate line unless compatibility data for the specific formulation support simultaneous infusion. The solution should not be mixed in the same container with amphotericin B, ciprofloxacin, or dobutamine; line flushing between incompatible agents uses 10 mL of compatible diluent. Serum magnesium monitoring is performed at 6 h intervals during continuous infusion, with a target range of 4.8–8.4 mg/dL cited in obstetric protocols for therapeutic seizure prophylaxis; deep tendon reflexes and respiratory rate are monitored to detect hypermagnesemia. The terminal product is a terminally sterilized small-volume parenteral that must meet USP <71> sterility, USP <85> endotoxin, and USP <788> particulate requirements.